

available at www.sciencedirect.comjournal homepage: www.elsevier.com/locate/rmed

CORRIGENDUM

Corrigendum to “The use of omalizumab in the treatment of severe allergic asthma: A clinical experience update” [Respiratory Medicine 103 (2009) 1098–1113]

Stephen Holgate^{a,*}, Roland Buhl^b, Jean Bousquet^c, Nicola Smith^d,
Zoya Panahloo^d, Pablo Jimenez^e

^a Infection, Inflammation and Repair Division, School of Medicine, University of Southampton, D level Centre Block (MP810), Southampton General Hospital, Tremona Road, Southampton SO16 6YD, UK

^b Mainz University Hospital, 55131 Mainz, Germany

^c Hôpital Arnaud de Villeneuve, FR-34000 Montpellier, France

^d Novartis Horsham Research Centre, Horsham, RH12 5AB, UK

^e Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936-1080, USA

The authors regret that incorrect data was published within the ‘Evaluating Clinical Response’ section, para 2 on page 1106. The correct data is printed below.

In responders, annualized rates of clinically significant exacerbations were reduced by 60% (0.73 vs 1.84, $P < 0.0001$ vs placebo), severe exacerbations by 76% (0.24 vs 1.00, $P < 0.0001$ vs placebo) and total emergency visits by 76% (0.18 vs 0.77, $P < 0.0001$ vs placebo) (Novartis, data on file).

DOI of original article: 10.1016/j.rmed.2009.03.008.

* Corresponding author. Tel.: +44 (0) 23 8079 6960; fax: +44 (0) 23 8070 1771.

E-mail address: s.holgate@soton.ac.uk (S. Holgate).